Member Info for Doc.Daneeka

Well - no. I never joined the Reddit crew and can't remember ever reporting you. Deep wounds still I see.

Scinv i was never one of those posters. Spent considerable time fighting them in fact - which anyone who was there then will confirm. Was abused often for it. I did occasionally join others in telling you to eff off as I considered your contributions malevolent.

SD2019 - apologies. You've contributed a great deal to this board but you can't go posting that old smoke and mirrors stuff again. We've been there before.
If you know something then please share it. If you don't want to share it, keep it to yourself.

And if AZ are on manouevres in the background - to relate this back to Doc83's much more intersting thread from earier today - then it would also inevitably lead to us getting shafted. Unless STRIVE comes galloping over the hill, every other route forward involves a dilution or surrender of equity. So whether they want to or not - whether they're fine upstanding citizens or not (and I'm sure they are ) - the end result is the same for us. Spacman's prediction is the ugliest of the possible routes to salvation for the drug at least, but without funds all other scenarios lead in the same direction.
With luck STRIVE is still out there as a possibility. No good scientific reason why NIH wouldn't believe in the value of the drug's deep dive data - but equally the company has rowed so hard away from Covid that you do wonder if they've already been knocked back and the multi virus strategy is the response to that knock back.

"Wigster77 unfortunately no not at the moment as there are too many traders and low life (excluding yourself and a number of genuine posters and holders) who I do not want to benefit from such information. Indeed I will be doing a Jeremy Clarkson smile when the information comes to light and they get right royally burnt! "

I could tell you but I'll have to kill you eh SD2019. Pathetic. You have a long track record of these kind of secret squirrel posts pre- Sprinter readout. Always promising something amazing - usually a stellar RNS -and always proven wrong within days or even hours.
If the bb doesn't need Scinv crowing at our discomfort - it really doesn't need this kind of rampy junk either.

If you want to read positivity Sam - look at Fruits or Tommy. If you want bitter acrimony, study the posting history of MrC and Manifesto. Most of the rest of us sit somewhere between these polar extremes. Down but not out.

pay no atention Sam. Not sure exactly what Mani suspects you might be up to - but at 7.5p there's not much room for shenanigans.
We're all still hopeful of a trial - any trial that will move the company forward. The most optimistic scenario is that SNG might be included on the new and much delayed US inpatient trial STRIVE. Less optimistically the prospect of either a dilutory JV with a big pharma or a fundraise to pursue a future as a broad spectrum therapeutic in the post covid world. That's essentially where we are, but with nothing substantial from the company for many months, it's all guesswork.

that's a lot of cut and paste Fruits. Certainly the Trial Nursing Manager has a full time job but it's part time for everyone else - whether that's 1,2,3, 4 or whatever.
I'm not even sure what Synairgen would be doing with a large nursing staff at this point anyway. They last dosed a patient 14 months ago. How many nurses are on the books ?

absolutely TP and Fruits. Who cares frankly if there are 2 or 4 or even 6 nurses or who this Pedro is ?

Can't for the life of me imagine what 6 nurses would be doing - given they're only collecting blood and swabs on days 1, 3 & 7. Anyone who regularly has this kind of procedure knows it takes a matter of a couple of minutes at most. One nurse could do a whole ward in a couple of hours.
Would also say that if Synairgen say they are supplying "support in kind " - and this support equates to specialist equipment and nursing staff - this surely implies the staff remain on the Synairgen payroll. And even if they didn't the total cost for nurses would still be less than one senior salary.

Thanks Aether - good work. The key thing in all of this is what tests they're actually running . They'll have enough blood and swabs to cross reference all viruses for Ifn signals. Not much point in Synairgen's involvement if they don't produce specific data that points to interferons in general and SNG001 in particular.

Mani - yes it is a given - but people should understand that it will be a very big piece of the pie. (or of a consortium - a biog piece cut into 4 or 5 smaller pieces

https://twitter.com/ProfWilko/status/1638885818491371521

Meanwhiloe everyone else is after a piece of the same pie.

Remap-cap's flu trial also a non-diltory possibility - but that would just be for flu.

STRIVE is the only non-dilutory route forward. Everything else requires somebody else's cash. You can say JV if you like but nobody jvs to conduct a trial that costs more than the value of the company they're jv-ing with, without taking most of the pie

Agreed Size. Standing up the Sprinter deep dive still stills seems the easiest route forward - and if we get onto STRIVE that's what will be tested. Giving the drug earlier than Dexa to patients with the right profiling. We don't know why they haven't pursued this route to date but if they'd come to shareholders after the deep dive and asked for £30m more for a trial of this kind I'm sure we'd have stumped up.

Mani - yes it's a big leap from a non-drug trial to a P3 for everything everywhere all at once with SNG - but Janssen and (maybe) AZ are here for a reason and it can't just be philanthropy

That Hopkinson typo was fun - but I did get his name right later in the comment.

And any trial that arises from UNIVERSAL and included SNG001 would clearly be P2/3. Safety from hundreds of patients applies across the board and combined efficacy is at least at P2 level.

UNIVERSAL was conceived as the last patients were being recruited for Sprinter. We don't know whose idea it was but we can be reasonably certain that Tom Hopkinson was wearing both his UoS and Synairgen hats and that Synairgen was an important partner from the outset. It's reasonable to believe that it was expected to support the onward development of SNG001 post Covid approval as a multi-virus therapeutic.
When Sprinter failed the main thrust of Covid R&D was arrested but at the same time new positives arrived for COPD and LC - which supported the second , originally subsidiary work thread and turned the focus back towards UNIVERSAL.
As I said yesterday UNIVERSAL is exactly the multi-virus platform trial Synairgen have been looking for - lacking only the drug itself.
Is UNIVERSAL the main show now ? We all hope not, because despite what TW said in January, it will still take a very long time to complete the trial ( which is still only running in 2 hospitals despite an ambition for 10 - according to the registry anyway ) and produce the peer -reviewed data that will allow the trial to be adapted for SNG001. So we'd still have a very long wait.
And of course many of us still believe the case for SNG's inclusion on STRIVE to be compelling. I expected Paxlovid to be the next protease inhibitor to join STRIVE based on viral clearance - but this case has weakened recently. SNG is the only drug anywhere with strong Covid inpatient data - and its the deep dive showed a clear pathway to success even with SoC improvements.

So 2 arrows still in the air - remembering that UNIVERSAL is NOT Synairgen's trial but also believing with a reasonable degree of certainty, that when Tom Wilkinson wrote "Although there is no drug involved as yet " the unnamed absent drug he's talking about is certainly SNG001.

Amazing find Thinshins - this might have quietened some of the recent unrest on the bb. Incredible that they did so well just in Southampton in the last 4 months of 2022. " no drug involved as yet " is exactly the highlight phrase Fruits.
UNIVERSAL is of course the multi-virus trial RM and co have been banging on about - lacking only the addition of SNG001.

Well we're talking about it Mani in the absence of anything substantive to discuss about the real task at hand. It's also the only trial Synairgen are engaged on (albeit in a supportive way ) and if the company survives it may have a part to play in the multi-virus story. The discrepancy is interesting to me - and someone wil provide the answer I'm sure.